Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume 33, Issue 4, Pages 605-615
Publisher
Wiley
Online
2013-01-03
DOI
10.1111/liv.12098
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma
- (2012) Jeong Eun Kim et al. ONCOLOGY
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
- (2011) Sadahisa Ogasawara et al. Hepatology International
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
- (2011) Romain Coriat et al. PLoS One
- Differentiation of Focal Liver Lesions: Usefulness of Parametric Imaging with Contrast-enhanced US
- (2011) Anass Anaye et al. RADIOLOGY
- Reproducibility of Perfusion Parameters in Dynamic Contrast-Enhanced MRI of Lung and Liver Tumors: Effect on Estimates of Patient Sample Size in Clinical Trials and on Individual Patient Responses
- (2010) Chaan S. Ng et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
- (2010) N. Lassau et al. CLINICAL CANCER RESEARCH
- Parametric imaging for characterizing focal liver lesions in contrast-enhanced ultrasound
- (2010) N G Rognin et al. IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL
- Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results
- (2010) Nathalie Lassau et al. RADIOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy
- (2009) Masatoshi Kudo JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
- (2009) Thomas Reiberger et al. JOURNAL OF HEPATOLOGY
- Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient
- (2009) Wu-Shiung Huang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Sorafenib-Induced Liver Failure
- (2008) AMERICAN JOURNAL OF GASTROENTEROLOGY
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
- (2008) Marc Mejias et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started